• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

LENVATINIB Drug Record

  • Summary
  • Interactions
  • Claims
  • LENVATINIB chembl:CHEMBL1289601 ApprovedAntineoplastic

    Alternate Names:

    E-7080
    ER-203492-00
    LENVIMA
    LENVATINIB
    KISPLYX
    E7080
    LENVIMA®
    E 7080
    UNII-EE083865G2
    4-(3-CHLORO-4-(N'-CYCLOPROPYLUREIDO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE
    LENVATINIB MESYLATE
    4-{3-CHLORO-4-[(CYCLOPROPYLCARBAMOYL)AMINO]PHENOXY}-7-METHOXYQUINOLINE-6-CARBOXAMIDE
    chemidplus:417716-92-8
    chembl:CHEMBL1289601
    rxcui:1603296
    drugbank:09078
    pubchem.compound:9823820

    Drug Info:

    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    FDA Approval Renal cell carcinoma, Thyroid cancer
    Drug Class Kinase Inhibitors
    (4 More Sources)

    Publications:

    Matsui et al., 2008, E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition., Int. J. Cancer
    Tohyama et al., 2014, Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models., J Thyroid Res
    Huang et al., 2016, Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma., Mol. Cancer Ther.
    Hong et al., 2015, Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma., Clin. Cancer Res.
  • LENVATINIB   RET

    Interaction Score: 0.5

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    25295214 27496134 17943726


    Sources:
    TALC JAX-CKB CIViC

  • LENVATINIB   FLT4

    Interaction Score: 0.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name E7080
    Novel drug target Established target

    PMIDs:
    17943726


    Sources:
    TALC MyCancerGenome TdgClinicalTrial

  • LENVATINIB   FGFR1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    25295214 17943726


    Sources:
    TdgClinicalTrial JAX-CKB

  • LENVATINIB   NRAS

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    26169970


    Sources:
    JAX-CKB

  • LENVATINIB   KDR

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name E7080
    Novel drug target Established target
    Notes

    PMIDs:
    17943726


    Sources:
    TALC MyCancerGenome TdgClinicalTrial TTD

  • LENVATINIB   FGFR2

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    17943726


    Sources:
    TALC

  • LENVATINIB   FLT1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name E7080
    Novel drug target Established target
    Notes

    PMIDs:
    17943726


    Sources:
    TALC TdgClinicalTrial

  • LENVATINIB   KIT

    Interaction Score: 0.17

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name E7080
    Novel drug target Established target

    PMIDs:
    17943726


    Sources:
    TdgClinicalTrial

  • LENVATINIB   PDGFRA

    Interaction Score: 0.16

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name E7080
    Novel drug target Established target

    PMIDs:
    17943726


    Sources:
    TdgClinicalTrial

  • LENVATINIB   BRAF

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase I
    Response Type sensitive

    PMIDs:
    26169970


    Sources:
    JAX-CKB

  • LENVATINIB   PDGFRB

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name E7080
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • LENVATINIB   YES1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MyCancerGenome: LENVATINIB

    • Version: 20-Jun-2017

    Alternate Names:
    LENVATINIB Generic Name

    Drug Info:
    Drug Class Kinase Inhibitors
    FDA Approval Renal cell carcinoma, Thyroid cancer

    Publications:

  • TdgClinicalTrial: LENVATINIB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small molecule
    FDA Approval not approved

    Publications:

  • JAX-CKB: Lenvatinib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Hong et al., 2015, Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma., Clin. Cancer Res.
    Tohyama et al., 2014, Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models., J Thyroid Res

  • CIViC: LENVATINIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Huang et al., 2016, Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma., Mol. Cancer Ther.

  • DTC: LENVATINIB

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1289601 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TALC: LENVATINIB

    • Version: 12-May-2016

    Alternate Names:
    LENVATINIB Primary Drug Name
    LENVATINIB Drug Generic Name
    E7081 Drug Synonym

    Drug Info:

    Publications:

  • TTD: Lenvatinib

    • Version: 2020.06.01

    Alternate Names:
    D0R0FO TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1289601

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21